Feltham

FELTHAM, England - Innovative Powder Formulation of Metformin Designed to Facilitate Adherence by Increasing Patient Choice in the Treatment of Type 2 Diabetes, Now Available in France and the United Kingdom Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Glucophage(R) Powder for Oral Solution in Sachets, (metformin hydrochloride in 500mg, 850mg and 1000mg strengths) indicated for the first-line treatment of type 2 diabetes mellitus, is now licensed in France and the United Kingdom(1), the first European countries to launch this new formulation of Glucophage(R).